JonathanChengMD

PubMed

• Correction to: Resection of Isolated Pelvic Recurrences after Colorectal Surgery: Long-Term Results and Predictors of Improved Clinical Outcome.
  Leonard R Henry, Elin Sigurdson, Eric A Ross, John S Lee, James C Watson, Jonathan D Cheng, Gary M Freedman, Andre Konski, John P Hoffman> ;Annals of Surgical Oncology. 2021 Dec 1
• Correction to: Resection of Isolated Pelvic Recurrences after Colorectal Surgery: Long-Term Results and Predictors of Improved Clinical Outcome.
  Leonard R Henry, Elin Sigurdson, Eric A Ross, John S Lee, James C Watson, Jonathan D Cheng, Gary M Freedman, Andre Konski, John P Hoffman> ;Annals of Surgical Oncology. 2021 Dec 1
• Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy.
  Ayers, M.,Nebozhyn, M.,Cristescu, R.,McClanahan, T. K.,Perini, R.,Rubin, E.,Cheng, J. D.,Kaufman, D. R.,Loboda, A.> ;Clin. Cancer Res.. 2018 Nov 18
• Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.
  Cristescu, R.,Mogg, R.,Ayers, M.,Albright, A.,Murphy, E.,Yearley, J.,Sher, X.,Liu, X. Q.,Lu, H.,Nebozhyn, M.,Zhang, C.,Lunceford, J. K.,Joe, A.,Cheng, J.,Webber, A. L....> ;Science. 2018 Oct 13
• Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review.
  Lala, M.,Chirovsky, D.,Cheng, J. D.,Mayawala, K.> ;Oral Oncol.. 2018 Aug 18
• 6 citations
  Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radioth...
  Patrick M Boland, Joshua E. Meyer, Adam C. Berger, Steven J. Cohen, Tzahi Neuman, Harry S. Cooper, Anthony J. Olszanski, Monica Davey, Jonathan D. Cheng, Abraham Leben...> ;American Journal of Clinical Oncology. 2017 Aug 1
• 437 citations
  Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.
  Joshua Bauml, Tanguy Y. Seiwert, David G. Pfister, Francis P. Worden, Stephen V. Liu, Jill Gilbert, Nabil F. Saba, Jared Weiss, Lori J. Wirth, Ammar Sukari, Hyunseok K...> ;Journal of Clinical Oncology. 2017 Mar 22
• 25 citations
  A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.
  Shilpa Gupta, Guillem Argiles, Pamela N. Munster, Antoine Hollebecque, Olav Dajani, Jonathan D. Cheng, Ruixue Wang, Ann M. Swift, Alessandra Tosolini, Sarina Anne Piha...> ;Clinical Cancer Research. 2015 Dec 1
• 3 citations
  Analytical Validation of AmpliChip p53 Research Test for Archival Human Ovarian FFPE Sections
  Matthew J. Marton, Andrew R. McNamara, D. Michele Nikoloff, Aki Nakao, Jonathan D. Cheng> ;Plos One. 2015 Jun 30
• 22 citations
  A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers.
  Crystal S. Denlinger, Neal J. Meropol, Tianyu Li, Nancy L. Lewis, Paul F. Engstrom, Louis M. Weiner, Jonathan D. Cheng, R. Katherine Alpaugh, Harry S. Cooper, John J. ...> ;Clinical Colorectal Cancer. 2014 Jun 1
• 138 citations
  Extended Structure–Activity Relationship and Pharmacokinetic Investigation of (4-Quinolinoyl)glycyl-2-cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP)
  Koen Jansen, Leen Heirbaut, Robert Verkerk, Jonathan D. Cheng, Jurgen Joossens, Paul Cos, Louis Maes, Anne-Marie Lambeir, Ingrid De Meester, Koen Augustyns, Pieter Van...> ;Journal of Medicinal Chemistry. 2014 Mar 24
• 11 citations
  Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach.
  Allyson J. Ocean, Paul J. Christos, Joseph A. Sparano, Manish A. Shah, Rhonda K. Yantiss, Jonathan D. Cheng, Juan Lin, Michael Papetti, Dan Matulich, Felice Schnoll-Su...> ;Investigational New Drugs. 2014 Feb 15
• 11 citations
  Women at increased risk for cardiac toxicity following chemoradiation therapy for esophageal carcinoma
  L. Tait, Joshua E. Meyer, E. McSpadden, Jonathan D. Cheng, Frank A. Baciewicz, Neal J. Meropol, Steven J. Cohen, Antoinette J. Wozniak, Minsig Choi, Andre Konski> ;Practical Radiation Oncology. 2013 Oct 1
• 129 citations
  Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold.
  Koen Jansen, Leen Heirbaut, Jonathan D. Cheng, Jurgen Joossens, Oxana Ryabtsova, Paul Cos, Louis Maes, Anne-Marie Lambeir, Ingrid De Meester, Koen Augustyns, Pieter Va...> ;ACS Medicinal Chemistry Letters. 2013 Mar 25
• 14 citations
  Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens
  Jiping Zhang, Matthildi Valianou, Heidi H. Simmons, Matthew K. Robinson, Hyung-Ok Lee, Stefanie R. Mullins, Wayne A. Marasco, Gregory P. Adams, Louis M. Weiner, Jonath...> ;FASEB Journal. 2013 Feb 1
• 21 citations
  P2-Substituted N-Acylprolylpyrrolidine Inhibitors of Prolyl Oligopeptidase: Biochemical Evaluation, Binding Mode Determination, and Assessment in a Cellular Model of S...
  Pieter Van der Veken, Vilmos Fülöp, Dean Rea, Melanie Gérard, Roos Van Elzen, Jurgen Joossens, Jonathan D. Cheng, Veerle Baekelandt, Ingrid De Meester, Anne-Marie Lamb...> ;Journal of Medicinal Chemistry. 2012 Nov 13
• 64 citations
  Activatable near-infrared fluorescent probe for in vivo imaging of fibroblast activation protein-alpha.
  Jinbo Li, Kai Chen, Hongguang Liu, Kai Cheng, Meng Yang, Jiping Zhang, Jonathan D. Cheng, Yan Zhang, Zhen Cheng> ;Bioconjugate Chemistry. 2012 Aug 15
• 11 citations
  The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients wit...
  Tracy Klayton, Tianyu Li, Jian Q. Yu, Lanea M.M. Keller, Jonathan D. Cheng, Steven J. Cohen, Neal J. Meropol, Walter Scott, Meng Xu-Welliver, Andre Konski> ;Journal of Gastrointestinal Cancer. 2012 Jul 10
• 54 citations
  Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiothe...
  Andre Konski, Tianyu Li, Michael Christensen, Jonathan D. Cheng, Jian Q. Yu, Kevin Crawford, Oleh Haluszka, Jeffrey L. Tokar, Walter J. Scott, Neal J. Meropol, Steven ...> ;Radiotherapy and Oncology. 2012 Jul 1
• 37 citations
  Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity.
  Oxana Ryabtsova, Koen Jansen, Sebastiaan Van Goethem, Jurgen Joossens, Jonathan D. Cheng, Anne-Marie Lambeir, Ingrid De Meester, Koen Augustyns, Pieter Van der Veken> ;Bioorganic & Medicinal Chemistry Letters. 2012 May 15
• 21 citations
  Cdc42 regulates extracellular matrix remodeling in three dimensions.
  Nisha S. Sipes, Yuxin Feng, Fukun Guo, Hyung-Ok Lee, Fu-Sheng Chou, Jonathan D. Cheng, James C. Mulloy, Yi Zheng> ;The Journal of Biological Chemistry. 2011 Oct 21
• 26 citations
  Evolution of Tumor Invasiveness: The Adaptive Tumor Microenvironment Landscape Model
  Hyung-Ok Lee, Ariosto S. Silva, Susanna Concilio, Yue-sheng Li, Michael Slifker, Robert A. Gatenby, Jonathan D. Cheng> ;Cancer Research. 2011 Oct 15
• 213 citations
  FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells
  Hyung-Ok Lee, Stefanie R. Mullins, Janusz Franco-Barraza, Matthildi Valianou, Edna Cukierman, Jonathan D. Cheng> ;BMC Cancer. 2011 Jun 13
• 3 citations
  Decreased Posttreatment SUV on PET Scan Is Associated With Improved Local Control in Medically Inoperable Esophageal Cancer.
  Navesh K. Sharma, Joshua S. Silverman, Tianyu Li, Jonathan D. Cheng, Jian Q. Yu, Oleh Haluszka, Walter J. Scott, Neal J. Meropol, Steven J. Cohen, Gary M. Freedman, An...> ;Gastrointestinal Cancer Research. 2011 May 1
• 32 citations
  Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma
  Igor Astsaturov, Neal J. Meropol, R. Katherine Alpaugh, Barbara Burtness, Jonathan D. Cheng, Sue McLaughlin, Andre Rogatko, Zhiheng Xu, James C. Watson, Louis M. Weine...> ;American Journal of Clinical Oncology. 2011 Feb 1
• Join now to see all

Journal Articles

• Pan-Tumor Genomic Biomarkers for PD-1 Checkpoint Blockade–Based Immunotherapy  
  Jonathan Cheng, Patrick A Ott, Elizabeth R Plimack, Antoni Ribas, Andrew Joe, Science Magazine